STOCK TITAN
  1. Home
  2. News
  3. LQDA

Liquidia Corporation - LQDA STOCK NEWS

Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.

Liquidia Corporation (NASDAQ: LQDA) is a U.S.-based biopharmaceutical company committed to enhancing drug delivery and efficacy through its proprietary PRINT® technology. The company focuses on the development, manufacturing, and commercialization of innovative therapies for pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia’s flagship product, YUTREPIA™, is an investigational inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension (PAH) and PH-ILD. This product aims to improve exercise ability and quality of life for patients.

Liquidia is actively advancing its product pipeline, which includes L606, an investigational sustained-release formulation of treprostinil administered through a next-generation nebulizer. Currently, L606 is under evaluation in an open-label study and aims to extend drug exposure while minimizing local irritation in the lungs.

In addition to these developments, Liquidia has a valuable collaboration with leading pharmaceutical companies, leveraging its PRINT® technology for broader therapeutic areas. This technology enables precise production of uniform drug particles, enhancing safety and efficacy, and can be applied to various therapeutic areas and routes of administration.

Recent achievements include the promotion of key leadership within the company as they prepare for the potential FDA approval and launch of YUTREPIA. The company has also successfully navigated regulatory and legal challenges, ensuring a clear path for YUTREPIA’s market entry.

Financially, Liquidia has demonstrated robust growth, reporting significant revenue from its partnership with Sandoz for the commercial sale of Treprostinil Injection. The company has also secured substantial funding through strategic agreements, bolstering its cash reserves for continued research and development efforts.

Liquidia remains dedicated to transforming patient care by addressing unmet needs with innovative drug delivery solutions and is poised to make significant strides in the biopharmaceutical industry.

News

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Rhea-AI Summary
Liquidia Corporation (LQDA) files counterclaims against United Therapeutics Corporation (UTHR) seeking dismissal of claims related to ‘793 patent and declaration that ‘327 patent is not infringed, invalid, and unenforceable in response to amended patent infringement complaint. Liquidia also asserts that UTHR failed to disclose prior art references and additional material information during prosecution of the ‘327 patent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
-
News

Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Rhea-AI Summary
Liquidia Corporation (LQDA) enrolled the first PH-ILD patient in the open-label ASCENT study for YUTREPIA and confirmed with the FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications. The FDA has tentatively approved YUTREPIA for PH-ILD with a PDUFA goal date of January 24, 2024. Liquidia also reached an agreement with the FDA regarding the registration requirements for L606 using the 505(b)(2) regulatory pathway, requiring only a single Phase 3 placebo-controlled efficacy trial in PH-ILD patients to support indications for both PAH and PH-ILD. The company is preparing to initiate a global study for L606 in 2024 and continues to enroll patients in an ongoing open-label, multicenter safety study of L606 in U.S. patients with PAH or PH-ILD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
none
-
News

Liquidia Corporation Announces $100 Million in New Financings

Rhea-AI Summary
Liquidia Corporation (LQDA) announced a $100 million capital raise through a private placement with Patient Square Capital and HealthCare Royalty, signaling confidence in the company's strategy and the value of its product YUTREPIA. The private placement of 7,182,532 shares of common stock at a purchase price of $10.442 per share is expected to yield gross proceeds of approximately $75.0 million. Additionally, an advance of $25.0 million was received from HealthCare Royalty under the current financing agreement. The company has now secured a total of $126 million in gross proceeds in the last month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.02%
Tags
none
News

Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) announced that Dr. Roger Jeffs, CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will be available via live webcast on Liquidia's website, with a replay and transcript archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
conferences
-
News

U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)

Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) announced that the U.S. Court of Appeals for the Federal Circuit affirmed the decision by the Patent Trial and Appeal Board, leading the company to pursue final FDA approval for YUTREPIA™ (treprostinil) inhalation. The company will also seek to set aside the injunction issued by the U.S. District Court and dismiss all claims related to the ‘793 patent in the second Hatch-Waxman lawsuit filed by United Therapeutics. Liquidia intends to defend itself against the allegations and focus on seeking final FDA approval for YUTREPIA to treat PAH and PH-ILD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
-
News

Liquidia Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) has priced an underwritten public offering of 3,491,620 shares of common stock at a public offering price of $7.16, resulting in total gross proceeds of approximately $25.0 million. The net proceeds are expected to fund ongoing commercial development of YUTREPIA™ (treprostinil) inhalation powder, continue development of YUTREPIA in other clinical trials, and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
offering
News

Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) reported financial results for Q3 2023, with cash totaling $76.2 million. They are preparing for upcoming key events, including an appeal of a PTAB decision on December 4, 2023, and the PDUFA goal date on January 24, 2024, for adding a PH-ILD indication to YUTREPIA's label.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
earnings
-
News

Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023

Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) will report its Q3 2023 financial results on November 7, 2023. A webcast will be held at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
conferences earnings
-
News

FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label

Rhea-AI Summary
Liquidia Corporation's amendment for YUTREPIA's new drug application has been accepted by the FDA for review. If approved, YUTREPIA would be indicated for the treatment of both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA has set a PDUFA goal date of January 24, 2024. The addition of the PH-ILD indication does not require new clinical studies. However, the launch of YUTREPIA is subject to ongoing litigation with United Therapeutics and final FDA approval. The FDA may not grant final approval for the PH-ILD indication until after the expiration of new clinical investigation exclusivity granted to Tyvaso on March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
clinical trial
News

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

Rhea-AI Summary
Liquidia Corporation faces patent infringement action by United Therapeutics Corporation under the Hatch-Waxman Act in response to Liquidia's amendment to its NDA for YUTREPIA. The '793 patent, previously ruled invalid by the PTAB, is asserted in the litigation, triggering a regulatory stay on FDA's final approval of YUTREPIA. The appeal of the PTAB decision is expected to be completed in Q4 2023 or H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
none

FAQ

What is the current stock price of Liquidia Corporation (LQDA)?

The current stock price of Liquidia Corporation (LQDA) is $15.49 as of February 28, 2025.

What is the market cap of Liquidia Corporation (LQDA)?

The market cap of Liquidia Corporation (LQDA) is approximately 1.3B.

What is Liquidia Corporation's primary focus?

Liquidia Corporation focuses on developing, manufacturing, and commercializing innovative therapies for pulmonary hypertension and pulmonary hypertension associated with interstitial lung disease using its proprietary PRINT® technology.

What is YUTREPIA?

YUTREPIA is an investigational inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What is PRINT® technology?

PRINT® technology is Liquidia's proprietary particle engineering platform that enables the precise production of uniform drug particles, enhancing safety and efficacy and applicable to various therapeutic areas and routes of administration.

What products are in Liquidia’s pipeline?

In addition to YUTREPIA, Liquidia is developing L606, an investigational sustained-release formulation of treprostinil administered through a next-generation nebulizer.

How does Liquidia generate revenue?

Liquidia generates revenue primarily from the sale of Treprostinil Injection through a partnership with Sandoz, as well as through strategic collaborations leveraging its PRINT® technology.

What recent leadership changes have occurred at Liquidia?

Recent leadership changes include the promotion of Michael Kaseta to Chief Operating Officer in addition to his role as Chief Financial Officer, and Michael Hunter to Senior Vice President of Manufacturing Operations.

What is the current status of YUTREPIA’s FDA approval?

YUTREPIA has received tentative approval from the FDA for the treatment of PAH, and Liquidia has filed an amendment to include PH-ILD. The FDA is expected to take final action on the amended NDA.

What are the financial highlights for Liquidia?

Liquidia reported significant revenue growth from its partnership with Sandoz, increased research and development expenses focused on YUTREPIA and L606, and strengthened cash reserves through strategic funding agreements.

What legal challenges has Liquidia faced?

Liquidia has navigated patent litigation and regulatory challenges, recently overcoming an injunction that had prevented FDA approval of YUTREPIA, and is actively defending against ongoing patent infringement claims.

How can I learn more about Liquidia Corporation?

For more information, visit Liquidia's official website at www.liquidia.com.
Stock LQDA logo
Liquidia Corporation

Nasdaq:LQDA

LQDA Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

LQDA Stock Data

1.30B
70.52M
19.49%
54.31%
12.25%
Biotechnology
Pharmaceutical Preparations
Link
United States
MORRISVILLE